Studies include Alpha, Beta, Gamma, Delta, Epsilon and Iota and it maintains antibodies for six months after the second dose
The collaboration will support Canada with direct access to rapid pandemic response capabilities
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
Production line at Lonza’s site in Geleen will complement the existing production network and support the manufacture of up to an additional 300 million doses per year
US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio
New agreement for three further production lines at Lonza’s site in Visp, Switzerland
These results were consistent across all clinically relevant patient subgroups regardless of key patient characteristics like age or sex, the cause of stroke or the severity of the stroke
This Orphan Drug Designation from the USFDA underlines the urgent medical need to develop a therapy for sickle cell disease
The approved scheme will deliver around 1 million sq ft of state-of-the-art laboratory and research space across a 12-acre site
The PRIOH-1 study met its primary endpoint, delivering statistically significant and clinically meaningful improvements in lesion healing
Subscribe To Our Newsletter & Stay Updated
